Biodexa Pharmaceuticals annual debt-to-equity ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Debt-to-Equity Ratio Growth & History (BDRX)
Biodexa Pharmaceuticals's debt-to-equity ratio was 0.01 for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.01 | −0.07 | −92.69% |
| 2024 | 2024-12-31 | 0.07 | 0.04 | +102.56% |
| 2023 | 2023-12-31 | 0.04 | −0.01 | −29.05% |
| 2022 | 2022-12-31 | 0.05 | 0.04 | +264.51% |
| 2021 | 2021-12-31 | 0.01 | −0.02 | −53.08% |
| 2020 | 2020-12-31 | 0.03 | 0.01 | +41.32% |
| 2019 | 2019-12-31 | 0.02 | −0.07 | −76.26% |
| 2018 | 2018-12-31 | 0.09 | −0.10 | −52.99% |
| 2017 | 2017-12-31 | 0.19 | 0.14 | +299.98% |
| 2016 | 2016-12-31 | 0.05 | 0.01 | +13.48% |
| 2015 | 2015-12-31 | 0.04 | — | — |
Biodexa Pharmaceuticals quarterly debt-to-equity ratio
Q4.18
Q4.19
Q4.20
Q4.21
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.01 | −0.07 | −92.69% |
| Q2 2025 | 2025-06-30 | 0.04 | 0.02 | +119.72% |
| Q4 2024 | 2024-12-31 | 0.07 | 0.04 | +102.56% |
| Q2 2024 | 2024-06-30 | 0.02 | −0.01 | −35.58% |
| Q4 2023 | 2023-12-31 | 0.04 | −0.01 | −29.05% |
| Q2 2023 | 2023-06-30 | 0.03 | — | — |
| Q4 2022 | 2022-12-31 | 0.05 | 0.04 | +264.51% |
| Q4 2021 | 2021-12-31 | 0.01 | −0.02 | −53.08% |
| Q4 2020 | 2020-12-31 | 0.03 | 0.01 | +41.32% |
| Q4 2019 | 2019-12-31 | 0.02 | −0.07 | −76.26% |
| Q4 2018 | 2018-12-31 | 0.09 | — | — |
Biodexa Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Biodexa Pharmaceuticals's debt-to-equity ratio decreased from 0.03 to 0.01, a change of −0.02. The latest reported quarter, Q4 2025, shows 0.01.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...